Capital International Investors
GRCL

Capital International Investors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Capital International Investors’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,093,416
Closed -$12.6M – 488
2021
Q4 		$12.6M Buy
2,093,416
+693,928
+50% +$6.67M ﹤0.01% 417
2021
Q3 		$19.4M Buy
1,399,488
+276,955
+25% +$3.27M ﹤0.01% 405
2021
Q2 		$14.6M Hold
1,122,533
– – ﹤0.01% 416
2021
Q1 		$17.3M Buy
+1,122,533
New +$26.5M ﹤0.01% 397

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Capital International Investors's GRCL Position: Q1 2022 in Review

Capital International Investors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2022, closing a stake of 2,093,416 shares — an estimated $12.6M sold.

Capital International Investors first reported a position in GRCL in Q1 2021 and held it in 4 quarters. The position peaked at $19.4M in Q3 2021. 34 funds tracked by Wall St. Rank hold GRCL as of Q1 2022.

  • Capital International Investors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2022 after selling out during the quarter.
  • Capital International Investors sold 2,093,416 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2022, an estimated $12.6M.
  • Capital International Investors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 4 quarters.
  • Capital International Investors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $19.4M in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2022.

Based on Capital International Investors's 13F filing for Q1 2022, filed 16 May 2022.